Analysts expect that BioTelemetry Inc (NASDAQ:BEAT) will announce $0.46 earnings per share (EPS) for the current quarter, Zacks Investment Research reports. Three analysts have made estimates for BioTelemetry’s earnings, with the lowest EPS estimate coming in at $0.44 and the highest estimate coming in at $0.48. BioTelemetry also reported earnings per share of $0.46 in the same quarter last year. The company is scheduled to report its next earnings report on Wednesday, July 24th.

On average, analysts expect that BioTelemetry will report full year earnings of $1.91 per share for the current financial year, with EPS estimates ranging from $1.81 to $2.01. For the next financial year, analysts anticipate that the company will post earnings of $2.09 per share, with EPS estimates ranging from $1.95 to $2.20. Zacks Investment Research’s EPS averages are an average based on a survey of sell-side research analysts that follow BioTelemetry.

BioTelemetry (NASDAQ:BEAT) last announced its earnings results on Thursday, April 25th. The medical research company reported $0.42 earnings per share (EPS) for the quarter, hitting the Zacks’ consensus estimate of $0.42. BioTelemetry had a net margin of 11.86% and a return on equity of 23.36%. The firm had revenue of $103.98 million for the quarter, compared to analyst estimates of $104.17 million. During the same quarter in the prior year, the business posted $0.39 EPS. The business’s revenue was up 10.0% compared to the same quarter last year.

A number of brokerages have issued reports on BEAT. Zacks Investment Research upgraded shares of BioTelemetry from a “sell” rating to a “hold” rating in a research report on Thursday, May 2nd. BidaskClub lowered shares of BioTelemetry from a “buy” rating to a “hold” rating in a research report on Tuesday, April 30th. Dougherty & Co restated a “buy” rating and set a $75.00 target price (down previously from $81.00) on shares of BioTelemetry in a research report on Friday, April 26th. Benchmark set a $82.00 target price on shares of BioTelemetry and gave the stock a “buy” rating in a research report on Tuesday, April 2nd. Finally, ValuEngine lowered shares of BioTelemetry from a “buy” rating to a “hold” rating in a research report on Monday, April 1st. Three investment analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. The company currently has a consensus rating of “Buy” and a consensus target price of $79.57.

In other BioTelemetry news, Director Kirk E. Gorman sold 5,518 shares of the stock in a transaction that occurred on Tuesday, April 30th. The shares were sold at an average price of $54.37, for a total transaction of $300,013.66. Following the transaction, the director now owns 178,833 shares in the company, valued at approximately $9,723,150.21. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Corporate insiders own 6.50% of the company’s stock.

Several hedge funds and other institutional investors have recently bought and sold shares of BEAT. Pearl River Capital LLC boosted its position in shares of BioTelemetry by 104.0% during the 1st quarter. Pearl River Capital LLC now owns 408 shares of the medical research company’s stock worth $26,000 after acquiring an additional 208 shares in the last quarter. Financial Architects Inc acquired a new stake in shares of BioTelemetry during the 4th quarter worth approximately $30,000. Altshuler Shaham Ltd boosted its position in BioTelemetry by 1,883.8% in the fourth quarter. Altshuler Shaham Ltd now owns 2,321 shares of the medical research company’s stock valued at $42,000 after buying an additional 2,204 shares in the last quarter. Huntington National Bank boosted its position in BioTelemetry by 35.5% in the first quarter. Huntington National Bank now owns 680 shares of the medical research company’s stock valued at $43,000 after buying an additional 178 shares in the last quarter. Finally, We Are One Seven LLC acquired a new stake in BioTelemetry in the fourth quarter valued at approximately $44,000. Institutional investors and hedge funds own 88.79% of the company’s stock.

Shares of NASDAQ:BEAT opened at $52.87 on Friday. BioTelemetry has a 12-month low of $39.50 and a 12-month high of $80.92. The company has a market cap of $1.81 billion, a price-to-earnings ratio of 27.23 and a beta of 1.32. The company has a current ratio of 1.99, a quick ratio of 1.84 and a debt-to-equity ratio of 0.57.

About BioTelemetry

BioTelemetry, Inc, a remote medical technology company, provides remote cardiac monitoring, remote blood glucose monitoring, centralized core lab services for clinical trials, and original equipment manufacturing services for healthcare and clinical research customers worldwide. It operates in Healthcare, Research, and Corporate and Other segments.

Recommended Story: Discover Your Risk Tolerance

Get a free copy of the Zacks research report on BioTelemetry (BEAT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for BioTelemetry (NASDAQ:BEAT)

Receive News & Ratings for BioTelemetry Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioTelemetry and related companies with MarketBeat.com's FREE daily email newsletter.